Recent findings that ARID1A deficiency is related to sensitivity to ICB therapy in multiple cancer types have paved the way of harnessing ARID1A as a novel target for cancer immunotherapy [11,62,63,64,65,66,67,68,69,70,71,72]. The gene discussed is ARID1A; the disease is cancer.